ICICI Prudential Asset Management Co Ltd Grows Stock Holdings in Bristol Myers Squibb Company $BMY

ICICI Prudential Asset Management Co Ltd lifted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 85.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 181,849 shares of the biopharmaceutical company’s stock after purchasing an additional 84,000 shares during the quarter. ICICI Prudential Asset Management Co Ltd’s holdings in Bristol Myers Squibb were worth $8,201,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. increased its stake in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $38,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $40,000. Finally, Mark Sheptoff Financial Planning LLC grew its holdings in shares of Bristol Myers Squibb by 233.3% during the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 700 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA accepted BMY’s NDA for an iberdomide combination in relapsed/refractory multiple myeloma and granted priority review (decision due Aug. 17, 2026). This raises the chance of a new revenue stream and short/medium‑term upside if approved. FDA Accepts BMY’s NDA
• Positive Sentiment: Coverage highlighting iberdomide review and BMY’s AI alliance frames new upside scenarios beyond core franchises — supportive sentiment for medium‑term growth prospects. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Positive Sentiment: Analyst commentary continues to underscore BMY’s durable oncology franchise as a core strength, which supports baseline cash flow and reduces execution risk relative to smaller biotech peers. Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Coverage noting BMY’s relative stability vs. the broader market — useful context for defensive positioning but not an immediate catalyst. BMY Delivers Stability While S&P 500 Stays Volatile
• Neutral Sentiment: General “street” roundups summarize mixed analyst views; useful for gauging sentiment but contain no single market‑moving surprise. What Does The Street Have To Say About BMY?
• Negative Sentiment: Zacks Research issued multiple downward revisions to quarterly and FY2027 EPS (examples: Q1 2026 cut to $1.40 from $1.50; Q3 2027 to $1.51 from $1.57; FY2027 to $5.71 from $5.90). Those cuts signal the analyst community trimming growth/earnings expectations and are the primary near‑term negative driver weighing on the stock.

Analyst Upgrades and Downgrades

BMY has been the topic of several analyst reports. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Guggenheim reaffirmed a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Piper Sandler reaffirmed an “overweight” rating and set a $66.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 28th. Leerink Partners boosted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Nine analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $60.19.

Bristol Myers Squibb Stock Up 1.0%

Shares of BMY stock opened at $60.32 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The stock has a market cap of $122.85 billion, a P/E ratio of 17.49, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a 50 day simple moving average of $56.05 and a two-hundred day simple moving average of $49.86.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company’s revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a $0.63 dividend. The ex-dividend date was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.